Flurry of AI Diagnostic Tools Receive FDA Clearance
Several companies have recently received FDA clearance for AI-powered diagnostic software, signaling a rapid expansion of AI in clinical workflows. The approvals include Copan’s PhenoMATRIX® for clinical microbiology image assessment, QuantalX Neuroscience’s Delphi MD for non-invasive brain function assessment, and HeartLung's AI-CVD® for opportunistic CT screening. Retia Medical also gained clearance for its Argos Infinity™ cardiovascular intelligence software.
- The global AI in radiology market was valued at approximately $1.41 billion in 2025 and is projected to reach nearly $11.84 billion by 2036. This growth is driven by the demand for early disease detection and the expansion of automated diagnostic systems. North America currently holds the largest market share. - To regulate the growing number of AI/ML-enabled devices, the FDA has implemented a framework focused on the total product lifecycle. This includes a "Predetermined Change Control Plan" that allows manufacturers to make certain algorithm modifications without needing a new regulatory submission for each change. - The American College of Radiology (ACR) is developing practice parameters for the use of AI in clinical settings. These guidelines are intended to address governance, performance monitoring, and bias mitigation. The ACR also offers a program called ARCH-AI to recognize facilities that adhere to best practices for AI in imaging. - A significant driver for AI adoption is the ongoing radiologist shortage, with demand for imaging services expected to outpace the supply of radiologists through 2055. Rising imaging volumes, an aging population, and workforce burnout are key factors contributing to this shortage. - There is a major trend of shifting diagnostic imaging services away from hospitals to outpatient settings like freestanding imaging centers. This shift is driven by lower costs, site-neutral payment policies from payers like CMS, and patient convenience. About 40% of all radiology volume is now performed in outpatient settings. - Recent Medicare reimbursement changes have created a mixed financial landscape. While the 2025 Medicare Physician Fee Schedule included a reduction in the conversion factor affecting many imaging procedures, CMS increased payments for certain procedures like coronary CT angiography (CCTA). - For 2026, the Centers for Medicare & Medicaid Services (CMS) has finalized a 2.6% increase in Hospital Outpatient Prospective Payment System (HOPPS) payment rates. CMS is also exploring future rulemaking for AI-specific reimbursement under this system. - The majority of AI-enabled radiology devices cleared by the FDA are classified as Class II medical devices, requiring a 510(k) clearance pathway which demonstrates "substantial equivalence" to an existing device.
